{
    "body": "Is sonidegib effective for basal cell carcinoma?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26867946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27189494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27636236", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26566923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26780190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26546616", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27695345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27538055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26833519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26323341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27511905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24773312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25646180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27067394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27096888", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26614022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27376162"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0007117", 
            "o": "http://linkedlifedata.com/resource/umls/label/A18627521"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18627521", 
            "o": "basal cell carcinomas"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0007117", 
            "o": "http://linkedlifedata.com/resource/umls/label/A0474410"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0474410", 
            "o": "basal cell carcinoma"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0007117", 
            "o": "BCC"
        }
    ], 
    "ideal_answer": [
        "Yes. Sonidegib, an oral smoothened antagonist, is indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation therapy, or adults with recurrent laBCC following surgery or radiation therapy."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002280", 
        "http://www.disease-ontology.org/api/metadata/DOID:2513"
    ], 
    "type": "yesno", 
    "id": "589a246f78275d0c4a000034", 
    "snippets": [
        {
            "offsetInBeginSection": 253, 
            "offsetInEndSection": 556, 
            "text": "This review of the literature aims to describe previous and current treatment options for oral therapy in locally advanced and metastatic NMSC otherwise unamenable to standard treatment. Oral Smoothened (Smo) inhibitors Vismodegib, Sonidegib, and Taladegib have shown to be effective in several trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566923", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 589, 
            "offsetInEndSection": 745, 
            "text": "Sonidegib is a new smoothened inhibitor currently under investigation for treatment of laBCC, which demonstrates a comparable safety profile to vismodegib. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780190", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 881, 
            "offsetInEndSection": 1067, 
            "text": "The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26833519", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 278, 
            "text": "Sonidegib (Odomzo\u00ae), an oral smoothened (SMO) antagonist, is indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation therapy, or adults with recurrent laBCC following surgery or radiation therapy. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26867946", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1290, 
            "offsetInEndSection": 1620, 
            "text": "The acceptable benefit-risk profile of sonidegib, along with a paucity of treatment options and the seriousness of the condition, makes sonidegib an emerging option for the treatment of adults with laBCC that has recurred following surgery or radiation therapy, or in those who are not candidates for surgery or radiation therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26867946", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 59, 
            "text": "Sonidegib phosphate: new approval for basal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376162", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 91, 
            "text": "Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695345", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 2322, 
            "offsetInEndSection": 2734, 
            "text": "Serious adverse events occurred in 11 (14%) of 79 patients in the 200 mg group and 45 (30%) of 150 patients in the 800 mg group.The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.Novartis Pharmaceuticals Corporation.<CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 591, 
            "offsetInEndSection": 956, 
            "text": "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646180", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 626, 
            "text": "The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.This report provides long-term follow-up data collected up to 12\u00a0months after the last patient was randomized.In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to sonidegib 200 or 800\u00a0mg. The primary end point was objective response rate assessed by central review.Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced B", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067394", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2322, 
            "offsetInEndSection": 2735, 
            "text": "Serious adverse events occurred in 11 (14%) of 79 patients in the 200 mg group and 45 (30%) of 150 patients in the 800 mg group.The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.Novartis Pharmaceuticals Corporation.<CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</C", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 384, 
            "offsetInEndSection": 709, 
            "text": "Oral sonidegib is approved in Switzerland for the treatment of adult patients with advanced basal cell carcinoma (BCC) and in the US and EU for the treatment of adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26323341", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 60, 
            "text": "Sonidegib phosphate: new approval for basal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376162", 
            "endSection": "title"
        }
    ]
}